Skip to main content
. 2024 Feb 5;3:18. Originally published 2023 Apr 14. [Version 2] doi: 10.3310/nihropenres.13384.2

Figure 3. Changes to gastrointestinal symptoms experienced since starting on a CFTR modulator.

Figure 3.

3a: PwCF were asked to compare how their symptoms had been in the last 4 weeks, compared to prior to initiating modulator therapy. 3b: Reporting of gastrointestinal symptoms to HCPs in those people taking a CFTR modulator.